Suffolk Capital Management’s Biogen BIIB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2018
Q4
Sell
-38,917
Closed -$13.8M 128
2018
Q3
$13.8M Buy
+38,917
New +$13.4M 1.96% 13
2017
Q1
Sell
-4,412
Closed -$1.25M 135
2016
Q4
$1.25M Sell
4,412
-35,579
-89% -$10.5M 0.17% 117
2016
Q3
$12.5M Buy
+39,991
New +$11.8M 1.72% 16
2016
Q2
Sell
-13,072
Closed -$3.4M 139
2016
Q1
$3.4M Sell
13,072
-681
-5% -$180K 0.45% 60
2015
Q4
$4.21M Sell
13,753
-10,033
-42% -$2.88M 0.53% 58
2015
Q3
$6.94M Buy
23,786
+20,646
+658% +$6.82M 0.92% 41
2015
Q2
$1.27M Sell
3,140
-17,525
-85% -$7.03M 0.15% 127
2015
Q1
$8.73M Sell
20,665
-15,946
-44% -$6.28M 1.02% 37
2014
Q4
$12.4M Buy
36,611
+20,855
+132% +$6.75M 1.51% 27
2014
Q3
$5.21M Sell
15,756
-174
-1% -$57.4K 0.65% 59
2014
Q2
$5.02M Hold
15,930
0.61% 57
2014
Q1
$4.87M Buy
+15,930
New +$5.06M 0.6% 58

Other funds holding BIIB

Suffolk Capital Management's BIIB Position: Q4 2018 in Review

Suffolk Capital Management sold out of Biogen (BIIB) in Q4 2018, closing a stake of 38,917 shares — an estimated $13.8M sold.

Suffolk Capital Management first reported a position in BIIB in Q1 2014 and held it in 12 quarters. The position peaked at $13.8M in Q3 2018. 1,140 funds tracked by Wall St. Rank hold BIIB as of Q4 2018.

  • Suffolk Capital Management reported no remaining Biogen position as of Q4 2018 after selling out during the quarter.
  • Suffolk Capital Management sold 38,917 Biogen shares in Q4 2018, an estimated $13.8M.
  • Suffolk Capital Management first reported a position in Biogen in Q1 2014 and held it in 12 quarters.
  • Suffolk Capital Management's Biogen position peaked at $13.8M in Q3 2018.
  • 1,140 funds tracked by Wall St. Rank held Biogen as of Q4 2018.

Based on Suffolk Capital Management's 13F filing for Q4 2018, filed 23 Jan 2019.